+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Ulcerative Colitis Market - Global Forecast 2026-2032- Product Image
Ulcerative Colitis Market - Global Forecast 2026-2032- Product Image
New

Ulcerative Colitis Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 197 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 4985922
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The ulcerative colitis market is rapidly evolving, shaped by scientific innovation and changing regulations. Senior leaders must understand shifting operational and reimbursement complexities to effectively position their organizations for growth and resilience.

Market Snapshot: Ulcerative Colitis Market Overview

From 2025 to 2026, the ulcerative colitis market is expected to rise from USD 8.81 billion to USD 9.54 billion, with future projections estimating a value of USD 15.51 billion by 2032. This translates to a compound annual growth rate of 8.41%. Growth is powered by the introduction of new therapies, greater demand for outcomes-driven care, and payer requirements for efficiency in managing chronic conditions. Organizations face challenges requiring nimble adaptation amid evolving policy, increased competitive intensity, and variations in reimbursement frameworks across key regions.

Scope & Segmentation of the Ulcerative Colitis Market

  • Therapy Types: Addresses a comprehensive portfolio of treatments, including aminosalicylates, corticosteroids, biologics, immunomodulators, and small molecule drugs. Within biologics, categories such as anti-integrins, interleukin inhibitors, and tumor necrosis factor inhibitors support more targeted patient management strategies.
  • Distribution Channels: Hospital pharmacies play a central role in handling infusion therapies and reimbursement logistics. Online pharmacies facilitate access for those on oral and self-administered treatments. Retail outlets prioritize patient support and ongoing adherence education.
  • Route of Administration: Covers both injectable treatments (intravenous and subcutaneous) and oral medications. These routes offer flexibility for providers and patients, supporting improved adherence and workflow integration.
  • Line of Therapy: Segmentation spans first-line, second-line, and third-line or later treatment options. This allows for refined approach strategies tailored to both new diagnoses and treatment-refractory populations.
  • Patient Types: Market analysis encompasses adult and pediatric populations, emphasizing the importance of adaptable clinical protocols and specialized support systems for diverse age groups.
  • Disease Severity: Categories—mild, moderate, severe—inform escalation strategies and guide care coordination to address a spectrum of clinical needs.
  • Regional Coverage: Includes in-depth consideration of the Americas, Europe, Middle East & Africa, and Asia-Pacific. Each region manages distinct healthcare policy environments and reimbursement dynamics, influencing adoption trends and patient access.
  • Technology Evolution: Incorporates digital health advancements, biomarker-guided therapeutics, and remote monitoring. These enable streamlined clinical decision-making and real-world uptake of innovative therapies.

Key Takeaways: Strategic Insights for Decision-Makers

  • Precision medicine and biomarker technologies enable more tailored treatment pathways, optimizing therapeutic response and driving value-based care models.
  • Integration of mature digital health platforms enhances patient adherence, enables continuous remote monitoring, and facilitates real-world evidence collection across care networks.
  • Payers are prioritizing value demonstration, compelling therapy manufacturers to establish the safety, impact, and differentiation of their solutions while adapting contracting approaches.
  • Expansion of oral therapies and alternate delivery mechanisms necessitates more adaptable prescribing strategies and expanded patient access initiatives on both regional and global scales.
  • Supply chain stability is increasingly reliant on local manufacturing partnerships and diversified sourcing, helping organizations manage fluctuations and support uninterrupted care delivery.
  • Tailored approaches for subpopulations, including pediatric and hard-to-treat cohorts, are spurring more focused investment in support services, trial design, and innovation.

Tariff Impact: Policy Dynamics Shaping Supply Chains

Trade policy changes, notably in large pharmaceutical markets such as the United States, are introducing new complexities into the ulcerative colitis supply chain. Increased tariffs on raw materials and packaging imports are leading manufacturers to prioritize localization efforts and partner diversification. These responses are transforming procurement strategies and shifting distribution patterns. New market entrants may face barriers as established players renegotiate supply terms, prompting both providers and payers to reassess cost structures to maintain consistent therapy access.

Methodology & Data Sources

This analysis combines structured interviews with clinicians, payers, and supply chain leaders, alongside a review of peer-reviewed studies, regulatory data, and clinical registries. Data triangulation of observational outcomes and treatment patterns ensures reliability and relevance for decision-making.

Why This Report Matters

  • Integrates foundational clinical research with current commercial trends to guide durable therapy access and inform strategic planning.
  • Presents region-specific analysis of technology use, regulatory evolution, and operational imperatives relevant to all major international markets.
  • Prepares executive teams with a unified view of how innovation, supply chain resilience, and evolving payer demands intersect for actionable insights.

Conclusion

The ulcerative colitis market is defined by rapid clinical and commercial innovation, policy realignment, and evolving patient care models. Successful organizations will take integrated action to maximize resilience and deliver meaningful outcomes for all stakeholders.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Ulcerative Colitis Market, by Therapy Type
8.1. Aminosalicylates
8.1.1. Mesalamine
8.1.2. Sulfasalazine
8.2. Biologics
8.2.1. Anti Integrins
8.2.2. IL Inhibitors
8.2.3. TNF Inhibitors
8.2.3.1. Infliximab
8.2.3.2. Adalimumab
8.2.3.3. Golimumab
8.3. Corticosteroids
8.3.1. Prednisone
8.3.2. Budesonide
8.3.3. Hydrocortisone
8.4. Immunomodulators
8.4.1. Azathioprine
8.4.2. 6-Mercaptopurine
8.4.3. Methotrexate
8.5. Small Molecule Drugs
8.5.1. Tofacitinib
8.5.2. Upadacitinib
8.6. Surgery
9. Ulcerative Colitis Market, by Route of Administration
9.1. Injectable
9.1.1. Intravenous
9.1.2. Subcutaneous
9.2. Oral
9.3. Topical
10. Ulcerative Colitis Market, by Type
10.1. Ulcerative Proctitis
10.2. Proctosigmoiditis
10.3. Left-Sided Colitis
10.4. Extensive Colitis
11. Ulcerative Colitis Market, by Line Of Therapy
11.1. First Line
11.2. Second Line
11.3. Third Line & Beyond
12. Ulcerative Colitis Market, by Disease Severity
12.1. Mild
12.2. Moderate
12.3. Severe
13. Ulcerative Colitis Market, by Patient Type
13.1. Adult
13.2. Pediatric
14. Ulcerative Colitis Market, by Distribution Channel
14.1. Offline Pharmacy
14.2. Online Pharmacy
15. Ulcerative Colitis Market, by Region
15.1. Americas
15.1.1. North America
15.1.2. Latin America
15.2. Europe, Middle East & Africa
15.2.1. Europe
15.2.2. Middle East
15.2.3. Africa
15.3. Asia-Pacific
16. Ulcerative Colitis Market, by Group
16.1. ASEAN
16.2. GCC
16.3. European Union
16.4. BRICS
16.5. G7
16.6. NATO
17. Ulcerative Colitis Market, by Country
17.1. United States
17.2. Canada
17.3. Mexico
17.4. Brazil
17.5. United Kingdom
17.6. Germany
17.7. France
17.8. Russia
17.9. Italy
17.10. Spain
17.11. China
17.12. India
17.13. Japan
17.14. Australia
17.15. South Korea
18. United States Ulcerative Colitis Market
19. China Ulcerative Colitis Market
20. Competitive Landscape
20.1. Market Concentration Analysis, 2025
20.1.1. Concentration Ratio (CR)
20.1.2. Herfindahl Hirschman Index (HHI)
20.2. Recent Developments & Impact Analysis, 2025
20.3. Product Portfolio Analysis, 2025
20.4. Benchmarking Analysis, 2025
20.5. AbbVie Inc.
20.6. Abivax SA
20.7. Ajinomoto Pharmaceuticals Co., Ltd.
20.8. Amgen Inc.
20.9. Apotex Inc.
20.10. AstraZeneca plc
20.11. Bausch Health Companies Inc.
20.12. Biocon Limited
20.13. Boehringer Ingelheim GmbH
20.14. Bristol-Myers Squibb Company
20.15. Celltrion, Inc.
20.16. Dr. Falk Pharma GmbH
20.17. EA Pharma Co., Ltd.
20.18. Eli Lilly and Company
20.19. F. Hoffmann-La Roche AG
20.20. Ferring International Center S.A.
20.21. Fresenius Kabi AG
20.22. Galapagos NV
20.23. Gilead Sciences Inc.
20.24. Janssen Biotech, Inc. by Johnson & Johnson
20.25. Merck & Co., Inc.
20.26. Novartis AG
20.27. Pfizer Inc.
20.28. Samsung Bioepis Co., Ltd.
20.29. Sandoz International GmbH
20.30. Sanofi S.A.
20.31. Sun Pharmaceutical Industries Ltd.
20.32. Takeda Pharmaceutical Company Limited
20.33. Viatris Inc.
20.34. Zydus Lifesciences Limited
List of Figures
FIGURE 1. GLOBAL ULCERATIVE COLITIS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL ULCERATIVE COLITIS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL ULCERATIVE COLITIS MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY DISEASE SEVERITY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY PATIENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 13. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. UNITED STATES ULCERATIVE COLITIS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 15. CHINA ULCERATIVE COLITIS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL ULCERATIVE COLITIS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY AMINOSALICYLATES, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY AMINOSALICYLATES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY AMINOSALICYLATES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY AMINOSALICYLATES, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY MESALAMINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY MESALAMINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY MESALAMINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY SULFASALAZINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY SULFASALAZINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY SULFASALAZINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY ANTI INTEGRINS, BY REGION, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY ANTI INTEGRINS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY ANTI INTEGRINS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY IL INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY IL INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY IL INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY TNF INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY TNF INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY TNF INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY INFLIXIMAB, BY REGION, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY INFLIXIMAB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY INFLIXIMAB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY ADALIMUMAB, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY ADALIMUMAB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY ADALIMUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY GOLIMUMAB, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY GOLIMUMAB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY GOLIMUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY PREDNISONE, BY REGION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY PREDNISONE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY PREDNISONE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY BUDESONIDE, BY REGION, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY BUDESONIDE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY BUDESONIDE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY HYDROCORTISONE, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY HYDROCORTISONE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY HYDROCORTISONE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY IMMUNOMODULATORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY IMMUNOMODULATORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY AZATHIOPRINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY AZATHIOPRINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY AZATHIOPRINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY 6-MERCAPTOPURINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY 6-MERCAPTOPURINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY 6-MERCAPTOPURINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY METHOTREXATE, BY REGION, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY METHOTREXATE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY METHOTREXATE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY SMALL MOLECULE DRUGS, BY REGION, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY SMALL MOLECULE DRUGS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY SMALL MOLECULE DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY TOFACITINIB, BY REGION, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY TOFACITINIB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY TOFACITINIB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY UPADACITINIB, BY REGION, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY UPADACITINIB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY UPADACITINIB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY SURGERY, BY REGION, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY SURGERY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY ULCERATIVE PROCTITIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY ULCERATIVE PROCTITIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY ULCERATIVE PROCTITIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY PROCTOSIGMOIDITIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY PROCTOSIGMOIDITIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY PROCTOSIGMOIDITIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY LEFT-SIDED COLITIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY LEFT-SIDED COLITIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY LEFT-SIDED COLITIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 102. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY EXTENSIVE COLITIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 103. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY EXTENSIVE COLITIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 104. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY EXTENSIVE COLITIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 105. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 106. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 107. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 108. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 109. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 110. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 111. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 112. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY THIRD LINE & BEYOND, BY REGION, 2018-2032 (USD MILLION)
TABLE 113. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY THIRD LINE & BEYOND, BY GROUP, 2018-2032 (USD MILLION)
TABLE 114. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY THIRD LINE & BEYOND, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 115. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
TABLE 116. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY MILD, BY REGION, 2018-2032 (USD MILLION)
TABLE 117. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY MILD, BY GROUP, 2018-2032 (USD MILLION)
TABLE 118. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY MILD, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 119. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY MODERATE, BY REGION, 2018-2032 (USD MILLION)
TABLE 120. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY MODERATE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 121. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY MODERATE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 122. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY SEVERE, BY REGION, 2018-2032 (USD MILLION)
TABLE 123. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY SEVERE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 124. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY SEVERE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 125. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 126. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
TABLE 127. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 128. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 129. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 130. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 131. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 132. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 133. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY OFFLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 134. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY OFFLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 135. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY OFFLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 136. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 137. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 138. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 139. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 140. AMERICAS ULCERATIVE COLITIS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 141. AMERICAS ULCERATIVE COLITIS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 142. AMERICAS ULCERATIVE COLITIS MARKET SIZE, BY AMINOSALICYLATES, 2018-2032 (USD MILLION)
TABLE 143. AMERICAS ULCERATIVE COLITIS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 144. AMERICAS ULCERATIVE COLITIS MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
TABLE 145. AMERICAS ULCERATIVE COLITIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
TABLE 146. AMERICAS ULCERATIVE COLITIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
TABLE 147. AMERICAS ULCERATIVE COLITIS MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2032 (USD MILLION)
TABLE 148. AMERICAS ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 149. AMERICAS ULCERATIVE COLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 150. AMERICAS ULCERATIVE COLITIS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 151. AMERICAS ULCERATIVE COLITIS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 152. AMERICAS ULCERATIVE COLITIS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
TABLE 153. AMERICAS ULCERATIVE COLITIS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 154. AMERICAS ULCERATIVE COLITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 155. NORTH AMERICA ULCERATIVE COLITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 156. NORTH AMERICA ULCERATIVE COLITIS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 157. NORTH AMERICA ULCERATIVE COLITIS MARKET SIZE, BY AMINOSALICYLATES, 2018-2032 (USD MILLION)
TABLE 158. NORTH AMERICA ULCERATIVE COLITIS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 159. NORTH AMERICA ULCERATIVE COLITIS MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
TABLE 160. NORTH AMERICA ULCERATIVE COLITIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
TABLE 161. NORTH AMERICA ULCERATIVE COLITIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
TABLE 162. NORTH AMERICA ULCERATIVE COLITIS MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2032 (USD MILLION)
TABLE 163. NORTH AMERICA ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 164. NORTH AMERICA ULCERATIVE COLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 165. NORTH AMERICA ULCERATIVE COLITIS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 166. NORTH AMERICA ULCERATIVE COLITIS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 167. NORTH AMERICA ULCERATIVE COLITIS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
TABLE 168. NORTH AMERICA ULCERATIVE COLITIS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 169. NORTH AMERICA ULCERATIVE COLITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 170. LATIN AMERICA ULCERATIVE COLITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 171. LATIN AMERICA ULCERATIVE COLITIS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 172. LATIN AMERICA ULCERATIVE COLITIS MARKET SIZE, BY AMINOSALICYLATES, 2018-2032 (USD MILLION)
TABLE 173. LATIN AMERICA ULCERATIVE COLITIS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 174. LATIN AMERICA ULCERATIVE COLITIS MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
TABLE 175. LATIN AMERICA ULCERATIVE COLITIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
TABLE 176. LATIN AMERICA ULCERATIVE COLITIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
TABLE 177. LATIN AMERICA ULCERATIVE COLITIS MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2032 (USD MILLION)
TABLE 178. LATIN AMERICA ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 179. LATIN AMERICA ULCERATIVE COLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 180. LATIN AMERICA ULCERATIVE COLITIS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 181. LATIN AMERICA ULCERATIVE COLITIS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 182. LATIN AMERICA ULCERATIVE COLITIS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
TABLE 183. LATIN AMERICA ULCERATIVE COLITIS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 184. LATIN AMERICA ULCERATIVE COLITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 185. EUROPE, MIDDLE EAST & AFRICA ULCERATIVE COLITIS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 186. EUROPE, MIDDLE EAST & AFRICA ULCERATIVE COLITIS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 187. EUROPE, MIDDLE EAST & AFRICA ULCERATIVE COLITIS MARKET SIZE, BY AMINOSALICYLATES, 2018-2032 (USD MILLION)
TABLE 188. EUROPE, MIDDLE EAST & AFRICA ULCERATIVE COLITIS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 189. EUROPE, MIDDLE EAST & AFRICA ULCERATIVE COLITIS MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
TABLE 190. EUROPE, MIDDLE EAST & AFRICA ULCERATIVE COLITIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
TABLE 191. EUROPE, MIDDLE EAST & AFRICA ULCERATIVE COLITIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
TABLE 192. EUROPE, MIDDLE EAST & AFRICA ULCERATIVE COLITIS MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2032 (USD MILLION)
TABLE 193. EUROPE, MIDDLE EAST & AFRICA ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 194. EUROPE, MIDDLE EAST & AFRICA ULCERATIVE COLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 195. EUROPE, MIDDLE EAST & AFRICA ULCERATIVE COLITIS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 196. EUROPE, MIDDLE EAST & AFRICA ULCERATIVE COLITIS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 197. EUROPE, MIDDLE EAST & AFRICA ULCERATIVE COLITIS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
TABLE 198. EUROPE, MIDDLE EAST & AFRICA ULCERATIVE COLITIS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 199. EUROPE, MIDDLE EAST & AFRICA ULCERATIVE COLITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 200. EUROPE ULCERATIVE COLITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 201. EUROPE ULCERATIVE COLITIS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 202. EUROPE ULCERATIVE COLITIS MARKET SIZE, BY AMINOSALICYLATES, 2018-2032 (USD MILLION)
TABLE 203. EUROPE ULCERATIVE COLITIS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 204. EUROPE ULCERATIVE COLITIS MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
TABLE 205. EUROPE ULCERATIVE COLITIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
TABLE 206. EUROPE ULCERATIVE COLITIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
TABLE 207. EUROPE ULCERATIVE COLITIS MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2032 (USD MILLION)
TABLE 208. EUROPE ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 209. EUROPE ULCERATIVE COLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 210. EUROPE ULCERATIVE COLITIS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 211. EUROPE ULCERATIVE COLITIS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 212. EUROPE ULCERATIVE COLITIS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
TABLE 213. EUROPE ULCERATIVE COLITIS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 214. EUROPE ULCERATIVE COLITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 215. MIDDLE EAST ULCERATIVE COLITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 216. MIDDLE EAST ULCERATIVE COLITIS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 217. MIDDLE EAST ULCERATIVE COLITIS MARKET SIZE, BY AMINOSALICYLATES, 2018-2032 (USD MILLION)
TABLE 218. MIDDLE EAST ULCERATIVE COLITIS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 219. MIDDLE EAST ULCERATIVE COLITIS MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
TABLE 220. MIDDLE EAST ULCERATIVE COLITIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
TABLE 221. MIDDLE EAST ULCERATIVE COLITIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
TABLE 222. MIDDLE EAST ULCERATIVE COLITIS MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2032 (USD MILLION)
TABLE 223. MIDDLE EAST ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 224. MIDDLE EAST ULCERATIVE COLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 225. MIDDLE EAST ULCERATIVE COLITIS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 226. MIDDLE EAST ULCERATIVE COLITIS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 227. MIDDLE EAST ULCERATIVE COLITIS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
TABLE 228. MIDDLE EAST ULCERATIVE COLITIS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 229. MIDDLE EAST ULCERATIVE COLITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 230. AFRICA ULCERATIVE COLITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 231. AFRICA ULCERATIVE COLITIS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 232. AFRICA ULCERATIVE COLITIS MARKET SIZE, BY AMINOSALICYLATES, 2018-2032 (USD MILLION)
TABLE 233. AFRICA ULCERATIVE COLITIS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 234. AFRICA ULCERATIVE COLITIS MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
TABLE 235. AFRICA ULCERATIVE COLITIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
TABLE 236. AFRICA ULCERATIVE COLITIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
TABLE 237. AFRICA ULCERATIVE COLITIS MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2032 (USD MILLION)
TABLE 238. AFRICA ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 239. AFRICA ULCERATIVE COLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 240. AFRICA ULCERATIVE COLITIS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 241. AFRICA ULCERATIVE COLITIS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 242. AFRICA ULCERATIVE COLITIS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
TABLE 243. AFRICA ULCERATIVE COLITIS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 244. AFRICA ULCERATIVE COLITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 245. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 246. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 247. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY AMINOSALICYLATES, 2018-2032 (USD MILLION)
TABLE 248. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 249. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
TABLE 250. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
TABLE 251. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
TABLE 252. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2032 (USD MILLION)
TABLE 253. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 254. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 255. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 256. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 257. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
TABLE 258. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 259. ASIA-PACIFIC ULCERATIVE COLITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 260. GLOBAL ULCERATIVE COLITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 261. ASEAN ULCERATIVE COLITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 262. ASEAN ULCERATIVE COLITIS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 263. ASEAN ULCERATIVE COLITIS MARKET SIZE, BY AMINOSALICYLATES, 2018-2032 (USD MILLION)
TABLE 264. ASEAN ULCERATIVE COLITIS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 265. ASEAN ULCERATIVE COLITIS MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
TABLE 266. ASEAN ULCERATIVE COLITIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
TABLE 267. ASEAN ULCERATIVE COLITIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
TABLE 268. ASEAN ULCERATIVE COLITIS MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2032 (USD MILLION)
TABLE 269. ASEAN ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 270. ASEAN ULCERATIVE COLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 271. ASEAN ULCERATIVE COLITIS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 272. ASEAN ULCERATIVE COLITIS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 273. ASEAN ULCERATIVE COLITIS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
TABLE 274. ASEAN ULCERATIVE COLITIS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 275. ASEAN ULCERATIVE COLITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 276. GCC ULCERATIVE COLITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 277. GCC ULCERATIVE COLITIS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 278. GCC ULCERATIVE COLITIS MARKET SIZE, BY AMINOSALICYLATES, 2018-2032 (USD MILLION)
TABLE 279. GCC ULCERATIVE COLITIS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 280. GCC ULCERATIVE COLITIS MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
TABLE 281. GCC ULCERATIVE COLITIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
TABLE 282. GCC ULCERATIVE COLITIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
TABLE 283. GCC ULCERATIVE COLITIS MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2032 (USD MILLION)
TABLE 284. GCC ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 285. GCC ULCERATIVE COLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 286. GCC ULCERATIVE COLITIS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 287. GCC ULCERATIVE COLITIS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 288. GCC ULCERATIVE COLITIS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
TABLE 289. GCC ULCERATIVE COLITIS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 290. GCC ULCERATIVE COLITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 291. EUROPEAN UNION ULCERATIVE COLITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 292. EUROPEAN UNION ULCERATIVE COLITIS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 293. EUROPEAN UNION ULCERATIVE COLITIS MARKET SIZE, BY AMINOSALICYLATES, 2018-2032 (USD MILLION)
TABLE 294. EUROPEAN UNION ULCERATIVE COLITIS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 295. EUROPEAN UNION ULCERATIVE COLITIS MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
TABLE 296. EUROPEAN UNION ULCERATIVE COLITIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
TABLE 297. EUROPEAN UNION ULCERATIVE COLITIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
TABLE 298. EUROPEAN UNION ULCERATIVE COLITIS MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2032 (USD MILLION)
TABLE 299. EUROPEAN UNION ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 300. EUROPEAN UNION ULCERATIVE COLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 301. EUROPEAN UNION ULCERATIVE COLITIS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 302. EUROPEAN UNION ULCERATIVE COLITIS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 303. EUROPEAN UNION ULCERATIVE COLITIS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
TABLE 304. EUROPEAN UNION ULCERATIVE COLITIS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 305. EUROPEAN UNION ULCERATIVE COLITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 306. BRICS ULCERATIVE COLITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 307. BRICS ULCERATIVE COLITIS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 308. BRICS ULCERATIVE COLITIS MARKET SIZE, BY AMINOSALICYLATES, 2018-2032 (USD MILLION)
TABLE 309. BRICS ULCERATIVE COLITIS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 310. BRICS ULCERATIVE COLITIS MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
TABLE 311. BRICS ULCERATIVE COLITIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
TABLE 312. BRICS ULCERATIVE COLITIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
TABLE 313. BRICS ULCERATIVE COLITIS MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2032 (USD MILLION)
TABLE 314. BRICS ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 315. BRICS ULCERATIVE COLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 316. BRICS ULCERATIVE COLITIS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 317. BRICS ULCERATIVE COLITIS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 318. BRICS ULCERATIVE COLITIS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
TABLE 319. BRICS ULCERATIVE COLITIS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 320. BRICS ULCERATIVE COLITIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 321. G7 ULCERATIVE COLITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 322. G7 ULCERATIVE COLITIS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
TABLE 323. G7 ULCERATIVE COLITIS MARKET SIZE, BY AMINOSALICYLATES, 2018-2032 (USD MILLION)
TABLE 324. G7 ULCERATIVE COLITIS MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
TABLE 325. G7 ULCERATIVE COLITIS MARKET SIZE, BY TNF INHIBITORS, 2018-2032 (USD MILLION)
TABLE 326. G7 ULCERATIVE COLITIS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
TABLE 327. G7 ULCERATIVE COLITIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2032 (USD MILLION)
TABLE 328. G7 ULCERATIVE COLITIS MARKET SIZE, BY SMALL MOLECULE DRUGS, 2018-2032 (USD MILLION)
TABLE 329. G7 ULCERATIVE COLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 330. G7 ULCERATIVE COLITIS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
TABLE 331. G7 ULCERATIVE COLITIS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 332. G7 ULCERATIVE COLITIS MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 333. G7 ULCERATIVE COLITIS MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
TABLE 334. G7 ULCERATIVE COLITIS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
TABLE 335. G7 ULCERATIVE

Companies Mentioned

The key companies profiled in this Ulcerative Colitis market report include:
  • AbbVie Inc.
  • Abivax SA
  • Ajinomoto Pharmaceuticals Co., Ltd.
  • Amgen Inc.
  • Apotex Inc.
  • AstraZeneca plc
  • Bausch Health Companies Inc.
  • Biocon Limited
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Celltrion, Inc.
  • Dr. Falk Pharma GmbH
  • EA Pharma Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Ferring International Center S.A.
  • Fresenius Kabi AG
  • Galapagos NV
  • Gilead Sciences Inc.
  • Janssen Biotech, Inc. by Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Samsung Bioepis Co., Ltd.
  • Sandoz International GmbH
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Viatris Inc.
  • Zydus Lifesciences Limited

Table Information

Report AttributeDetails
No. of Pages197
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 9.54 Billion
Forecasted Market Value ( USD ) by 2032 $ 15.51 Billion
Compound Annual Growth Rate8.4%
Regions CoveredGlobal
No. of Companies Mentioned31

Related Topics

Related Reports

Ulcerative Colitis - Market Insight, Epidemiology, and Market Forecast - 2034 - Product Image

Ulcerative Colitis - Market Insight, Epidemiology, and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Ulcerative Colitis Market Report by Type, Disease Type, Molecule Type, Drug Type, Route of Administration, Distribution Channel, and Region 2025-2033 - Product Image

Ulcerative Colitis Market Report by Type, Disease Type, Molecule Type, Drug Type, Route of Administration, Distribution Channel, and Region 2025-2033

  • Report
  • 134 Pages
  • Global
From
Ulcerative Colitis Market Report 2025 - Product Image

Ulcerative Colitis Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Ulcerative Colitis Market Report and Forecast 2025-2034 - Product Image

Ulcerative Colitis Market Report and Forecast 2025-2034

  • Report
  • 400 Pages
  • Global
From
Ulcerative Colitis Drug Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Product Type - Product Image

Ulcerative Colitis Drug Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Product Type

  • Report
  • 99 Pages
  • Global
From

About the Ulcerative Colitis Drug Market

The Ulcerative Colitis Drug market is a subset of the Gastrointestinal Drugs market, which includes medications used to treat a variety of gastrointestinal disorders. Ulcerative Colitis Drugs are used to treat the chronic inflammatory bowel disease of the same name. These drugs are typically administered orally or intravenously, and can be used to reduce inflammation, improve symptoms, and induce and maintain remission. Commonly prescribed Ulcerative Colitis Drugs include aminosalicylates, corticosteroids, immunomodulators, and biologics. The Ulcerative Colitis Drug market is highly competitive, with many companies offering a variety of treatments. Some of the major players in the market include AbbVie, Pfizer, Takeda, Janssen, and UCB. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.